UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K/A
(Amendment No. 1)
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 24, 2007 (April 24, 2007)
Boston Life Sciences, Inc.
(Exact Name of Registrant as Specified in Charter)
| | | | | |
| Delaware | | 0-6533 | | 87-0277826 |
| |
(State or Other Juris-
diction of Incorporation | | (Commission
File Number) | | (IRS Employer
Identification No.) |
| | | |
| 85 Main Street, Hopkinton, Massachusetts | | 01748 |
| |
| (Address of Principal Executive Offices) | | (Zip Code) |
Registrant’s telephone number, including area code: (508) 497-2360
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (seeGeneral Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 4.01. Changes in Registrant’s Certifying Accountant
As disclosed by Boston Life Sciences, Inc. (the “Company”) in its Current Report on Form 8-K filed with the Securities and Exchange Commission on April 18, 2007, the Company dismissed PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm, and appointed McGladrey & Pullen, LLP independent registered public accounting firm, in each case effective April 18, 2007. The Company furnished a copy of the disclosures in such Form 8-K to PricewaterhouseCoopers LLP and requested that PricewaterhouseCoopers LLP furnish the Company with a letter addressed to the Securities and Exchange Commission stating whether or not it agreed with those disclosures. The Company is filing this amendment to such Form 8-K to provide a copy of the letter received from PricewaterhouseCoopers LLP, which is attached hereto as Exhibit 16 and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
| | (d) | | Exhibits |
| |
| | | | See Exhibit Index attached hereto. |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | |
| | Boston Life Sciences, Inc.
| |
| Date: April 24, 2007 | By: | /s/ Kenneth L. Rice, Jr. | |
| | | Kenneth L. Rice, Jr. | |
| | | Executive Vice President, Finance and
Administration and Chief Financial Officer | |
| |
EXHIBIT INDEX
| | | |
| Exhibit No. | | Description |
| | | |
| 16 | | Letter from PricewaterhouseCoopers LLP dated April 24, 2007, addressed to the Securities and Exchange Commission |
